RECURRENT HAIRY CELL LEUKEMIA
Clinical trials for RECURRENT HAIRY CELL LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HAIRY CELL LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT HAIRY CELL LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo aims to outshine standard care for rare leukemia
Disease control Recruiting nowThis study tests a combination of two drugs, tovorafenib and rituximab, in people with classical hairy cell leukemia that has returned or not responded to treatment. It also compares this new combo to the current standard treatment (cladribine plus rituximab) for newly diagnosed …
Matched conditions: RECURRENT HAIRY CELL LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 10:55 UTC
-
New hope for rare blood cancer: targeted pill takes on relapsed hairy cell leukemia
Disease control Recruiting nowThis study tests a daily pill called venetoclax for people whose hairy cell leukemia has returned after prior treatment. The drug blocks a protein that helps cancer cells survive. About 20 adults will take the medication to see if it can shrink tumors and restore normal blood cou…
Matched conditions: RECURRENT HAIRY CELL LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Promising combo targets rare leukemia in phase 2 trial
Disease control Recruiting nowThis study tests a two-step treatment for hairy cell leukemia, a rare blood cancer. First, patients receive cladribine chemotherapy to kill cancer cells, then rituximab immunotherapy to help the immune system attack any remaining cells. The goal is to achieve complete remission a…
Matched conditions: RECURRENT HAIRY CELL LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:53 UTC